Journal
ONCOIMMUNOLOGY
Volume 3, Issue 1, Pages -Publisher
TAYLOR & FRANCIS INC
DOI: 10.4161/onci.27817
Keywords
immune checkpoints; immunotherapy; mutational heterogeneity; PD-1; PD-L1
Categories
Funding
- BMS
- GSK
- MedImmune
- MSD
- Genentech
Ask authors/readers for more resources
Anti-PD-1/PD-L1 antibodies are emerging as promising anticancer therapeutics. Interestingly, elevated response rates to these agents are mostly documented among patients with tumors that bear high level of somatic mutations, like melanoma or non-small cell lung carcinoma. We herein formulate the hypothesis that high levels of mutational heterogeneity in the tumor could be the key for the success of immune checkpoint-targeting therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available